Login
Navigate Fool.com
Will CYCC beat
the market?
Community Rating: 2 Stars: Unattractive

3.25 0.07 (2.20%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.27
Previous Close $3.18
Daily Range $3.13 - $3.30
52-Week Range $2.91 - $8.18
Market Cap $35.4M
P/E Ratio -1.25
Dividend (Yield) $0.00 (0.0%)
Volume 796,807
Average Daily Volume 290,194
Current FY EPS $0.00

How do you think CYCC
will perform against the market?

Top CYCC Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted July 2, 2011

With the dilutive financing today, all the pieces are in place for Cyclacel to rebound in the second half: 1. Bad news out of the way. Selciclib failed in the APPRAISE trial and will no longer weigh … More

2 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted May 10, 2011

Cyclacel is carving out a new spike this month, undoubtedly related to ASCO's approach. But the company's presentations are unlikely to contain meaningful new data - the SEAMLESS phase III trial of sa … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Cyclacel Announces New Stock Issue

The pharmaceutical company hopes to reap gross proceeds of around $20 million from the offering.

Insiders at Lululemon and Restoration Hardware Sell Company Stock

Plus, there were noteworthy purchases at Ambit Biosciences and Cyclacel Pharmaceuticals.

Insiders at Lululemon and Restoration Hardware Sell Company Stock

U.S. HOT STOCKS FUTURES: HOT STOCKS TO WATCH

U.S. HOT STOCKS FUTURES: HOT STOCKS TO WATCH

Cyclacel Agrees to Sell Patents to Celgene; Litigation to Be Dismissed

5 of Last Week's Biggest Losers

These five stocks bucked last week's uptrend by taking a dive.

The Best of 2012 #7: Sunesis

After announcing an expansion of P3 trials for its acute myeloid leukemia drug, Sunesis Pharmaceuticals shot to new heights, up 325% for the year. That puts it at #7 on our list of the very best stocks in healthcare for 2012.

5 of Last Week's Biggest Winners

These five stocks soared over the past few days.

Cyclacel Pharma May Bring Huge Returns For The Long Term

See More CYCC News...

Sector

Healthcare

Industry

Drugs

CYCLACEL PHARMACEUTICALS, INC. (CYCC) Description

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Website: http://www.cyclacel.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks